Literature DB >> 23447566

Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells.

Amy S McKee1, Matthew A Burchill, Michael W Munks, Lei Jin, John W Kappler, Rachel S Friedman, Jordan Jacobelli, Philippa Marrack.   

Abstract

Many vaccines include aluminum salts (alum) as adjuvants despite little knowledge of alum's functions. Host DNA rapidly coats injected alum. Here, we further investigated the mechanism of alum and DNA's adjuvant function. Our data show that DNase coinjection reduces CD4 T-cell priming by i.m. injected antigen + alum. This effect is partially replicated in mice lacking stimulator of IFN genes, a mediator of cellular responses to cytoplasmic DNA. Others have shown that DNase treatment impairs dendritic cell (DC) migration from the peritoneal cavity to the draining lymph node in mice immunized i.p. with alum. However, our data show that DNase does not affect accumulation of, or expression of costimulatory proteins on, antigen-loaded DCs in lymph nodes draining injected muscles, the site by which most human vaccines are administered. DNase does inhibit prolonged T-cell-DC conjugate formation and antigen presentation between antigen-positive DCs and antigen-specific CD4 T cells following i.m. injection. Thus, from the muscle, an immunization site that does not require host DNA to promote migration of inflammatory DCs, alum acts as an adjuvant by introducing host DNA into the cytoplasm of antigen-bearing DCs, where it engages receptors that promote MHC class II presentation and better DC-T-cell interactions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23447566      PMCID: PMC3607057          DOI: 10.1073/pnas.1300392110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  CD8 T cell competition for dendritic cells in vivo is an early event in activation.

Authors:  Richard A Willis; John W Kappler; Philippa C Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

2.  Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors:  Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal:  Science       Date:  2006-12-22       Impact factor: 47.728

3.  Immunology: Toll-like receptors and antibody responses.

Authors:  D Nemazee; A Gavin; K Hoebe; B Beutler
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

4.  Naive and memory CD4+ T cell survival controlled by clonal abundance.

Authors:  Jason Hataye; James J Moon; Alexander Khoruts; Cavan Reilly; Marc K Jenkins
Journal:  Science       Date:  2006-03-02       Impact factor: 47.728

5.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes.

Authors:  F Crawford; H Kozono; J White; P Marrack; J Kappler
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

6.  Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release.

Authors:  Hanfen Li; Suba Nookala; Fabio Re
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

7.  Initial T cell frequency dictates memory CD8+ T cell lineage commitment.

Authors:  Amanda L Marzo; Kimberly D Klonowski; Agnes Le Bon; Persephone Borrow; David F Tough; Leo Lefrançois
Journal:  Nat Immunol       Date:  2005-07-17       Impact factor: 25.606

8.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

9.  TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.

Authors:  Ken J Ishii; Tatsukata Kawagoe; Shohei Koyama; Kosuke Matsui; Himanshu Kumar; Taro Kawai; Satoshi Uematsu; Osamu Takeuchi; Fumihiko Takeshita; Cevayir Coban; Shizuo Akira
Journal:  Nature       Date:  2008-02-07       Impact factor: 49.962

10.  CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo.

Authors:  Tim Worbs; Thorsten R Mempel; Jasmin Bölter; Ulrich H von Andrian; Reinhold Förster
Journal:  J Exp Med       Date:  2007-02-26       Impact factor: 14.307

View more
  57 in total

1.  How squalene GLAdly helps generate antigen-specific T cells via antigen-carrying neutrophils and IL-18.

Authors:  Justin D Kedl; Ross M Kedl
Journal:  Eur J Immunol       Date:  2015-02       Impact factor: 5.532

2.  Effective and lesion-free cutaneous influenza vaccination.

Authors:  Ji Wang; Bo Li; Mei X Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 3.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

4.  Adenosine triphosphate acts as a paracrine signaling molecule to reduce the motility of T cells.

Authors:  Chiuhui Mary Wang; Cristina Ploia; Fabio Anselmi; Adelaida Sarukhan; Antonella Viola
Journal:  EMBO J       Date:  2014-05-19       Impact factor: 11.598

Review 5.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.

Authors:  Charles Maisonneuve; Sylvie Bertholet; Dana J Philpott; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

6.  An evolving autoimmune microenvironment regulates the quality of effector T cell restimulation and function.

Authors:  Rachel S Friedman; Robin S Lindsay; Jason K Lilly; Vinh Nguyen; Caitlin M Sorensen; Jordan Jacobelli; Matthew F Krummel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-10       Impact factor: 11.205

7.  The Syk-NFAT-IL-2 Pathway in Dendritic Cells Is Required for Optimal Sterile Immunity Elicited by Alum Adjuvants.

Authors:  Hanif Javanmard Khameneh; Adrian W S Ho; Roberto Spreafico; Heidi Derks; Hazel Q Y Quek; Alessandra Mortellaro
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

Review 8.  Adjuvanted influenza vaccines.

Authors:  John S Tregoning; Ryan F Russell; Ekaterina Kinnear
Journal:  Hum Vaccin Immunother       Date:  2018-01-25       Impact factor: 3.452

Review 9.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

10.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.